BackgroundOne of the most significant recent advancements in cancer immunotherapy is the development of chimeric antigen receptor (CAR) technology. More recently, this approach has been gradually modified for the research associated with various treatment-resistant nonneoplastic diseases by engineering immune cells to provide precise targeting.ResultsThis narrative review discusses two primary therapeutic approaches the use of CAR technology in the treatment of nonneoplastic diseases.
One strategy involves the elimination of specific pathogenic cell populations. Specifically, by engineering T cells, macrophages, or natural killer (NK) cells, pathogenic cells can be eliminated in autoimmune disorders, infectious diseases, and fibrotic lesions.
The second approach aims to restore immune homeostasis by using engineered regulatory T cells (Tregs) to control augmented immune effector responses. This strategy has been shown to promote transplant tolerance and has therapeutic potential for inflammatory bowel disease and type 1 diabetes.
Frontiers in Immunology published a clinical update in Infectious Disease on 03 Jun 2026.
The item focuses on Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases.
Review the original article for the full source wording and details.